GlaxoSmithKline Biologicals SA
GlaxoSmithKline Biologicals SA is a drug establishment in Wavre, Belgium, registered with the US FDA under FEI 3003973577. Its registered operations are: Analytical testing, Labelling, Drug manufacture, Packaging, Sterilisation. 18 EU/UK GMP certificates are matched to this site, 17 inspected within the last three years.
Sources: FDA Drug Establishments Current Registration Site (checked 2 Nov 2026); EudraGMDP; MHRA GMDP. Methodology
Registered operations
Business operations this establishment declares in its FDA registration. Registration is not an approval and says nothing about EU or UK GMP status.
GMP documents matched to this site (18)
| Document | Authority | Inspection | Source |
|---|---|---|---|
BE/GMP/2026/056 GMP certificate | Competent authority of Belgium | 2 Jun 2026 within 3-year review window | EudraGMDP |
BE/GMP/2026/021 GMP certificate | Competent authority of Belgium | 6 Mar 2026 within 3-year review window | EudraGMDP |
BE/GMP/2026/020 GMP certificate | Competent authority of Belgium | 6 Mar 2026 within 3-year review window | EudraGMDP |
BE/GMP/2025/174 GMP certificate | Competent authority of Belgium | 5 Nov 2025 within 3-year review window | EudraGMDP |
BE/GMP/2025/117 GMP certificate | Competent authority of Belgium | 17 Oct 2025 within 3-year review window | EudraGMDP |
BE/GMP/2025/159 GMP certificate | Competent authority of Belgium | 12 Sept 2025 within 3-year review window | EudraGMDP |
BE/GMP/2025/100 GMP certificate | Competent authority of Belgium | 12 Sept 2025 within 3-year review window | EudraGMDP |
BE/GMP/2025/048 GMP certificate | Competent authority of Belgium | 23 May 2025 within 3-year review window | EudraGMDP |
BE/GMP/2025/031 GMP certificate | Competent authority of Belgium | 21 Jan 2025 within 3-year review window | EudraGMDP |
BE/GMP/2024/128 GMP certificate | Competent authority of Belgium | 20 Sept 2024 within 3-year review window | EudraGMDP |
BE/GMP/2024/074 GMP certificate | Competent authority of Belgium | 5 Jul 2024 within 3-year review window | EudraGMDP |
BE/GMP/2024/073 GMP certificate | Competent authority of Belgium | 5 Jul 2024 within 3-year review window | EudraGMDP |
BE/GMP/2024/165 GMP certificate | Competent authority of Belgium | 5 Jun 2024 within 3-year review window | EudraGMDP |
BE/GMP/2024/166 GMP certificate | Competent authority of Belgium | 5 Jun 2024 within 3-year review window | EudraGMDP |
BE/GMP/2024/025 GMP certificate | Competent authority of Belgium | 21 Mar 2024 within 3-year review window | EudraGMDP |
BE/GMP/2024/034 GMP certificate | Competent authority of Belgium | 20 Feb 2024 within 3-year review window | EudraGMDP |
BE/GMP/2023/118 GMP certificate | Competent authority of Belgium | 8 Nov 2023 within 3-year review window | EudraGMDP |
BE/GMP/2023/087 GMP certificate | Competent authority of Belgium | 19 Oct 2023 outside 3-year review window | EudraGMDP |
A GMP document is matched to this site when its address names the site's street and its city or postcode. In our latest internal review 59 of 60 sampled matches were the right site (not yet independently reviewed; measured match quality). Check the certificate's own address before relying on it. The three-year review window is the EMA guideline default after an inspection, not an official expiry date.
What this page does not show
- Which substances are made here: DMFs and CEPs are filed by organisations, not sites, so we do not link substances to this site.
- Capacity, scale, price or current availability: no regulator publishes these.
- FDA inspection classifications for this site, which are not yet linked.